How to Get Zetia (Ezetimibe) in Washington State

What Is Ezetimibe and Why Washington Patients Use It

Ezetimibe blocks cholesterol absorption at the intestinal brush border by inhibiting the Niemann-Pick C1-like 1 (NPC1L1) transporter, which lowers LDL cholesterol by roughly 18-20% when added to a statin. Washington clinicians prescribe it most often when statin therapy alone fails to bring LDL-C below the patient's target, when a patient cannot tolerate high-dose statins, or as monotherapy when statins are contraindicated entirely.

The landmark IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 showed that adding ezetimibe to simvastatin 40 mg reduced the composite of cardiovascular death, major coronary events, or stroke by 6.4% relative to simvastatin alone (32.7% vs. 34.7%; P<0.001) over a median 7-year follow-up in post-acute-coronary-syndrome patients [1]. Mean LDL-C at 1 year was 53.7 mg/dL in the combination group vs. 69.5 mg/dL in the simvastatin-only group [1]. Those numbers established ezetimibe as a legitimate second-line agent, not merely a bridge drug.

The FDA approved ezetimibe (Zetia) in 2002 as an adjunct to diet and statin therapy for primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia [2]. The standard adult dose is 10 mg orally once daily, taken with or without food, at any time of day. No renal dose adjustment is required; the drug is not recommended in moderate-to-severe hepatic impairment [2].

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD, ezetimibe is recommended as the first nonstatin to add when LDL-C remains above goal on maximally tolerated statin therapy" [3]. Washington providers follow this guideline closely in both primary care and cardiology practices.

Who Can Prescribe Zetia in Washington State

Any Washington-licensed prescriber with a valid DEA registration and state license can write a Zetia prescription because ezetimibe is a non-controlled medication. That group includes MDs, DOs, nurse practitioners, and physician assistants operating under their respective scopes of practice.

Washington State grants nurse practitioners full practice authority under RCW 18.79 [4]. An NP in Washington can assess, diagnose, and prescribe ezetimibe without physician oversight. Physician assistants (PAs) in Washington practice under a collaborative agreement with a supervising physician per WAC 246-918 [5], so a PA-issued Zetia prescription is valid as long as that agreement is current.

Telehealth prescribers must hold an active Washington medical license or a Washington telehealth provider certificate. The Washington Medical Commission confirms that out-of-state physicians providing telehealth services to Washington patients must obtain a Washington license unless they qualify for a narrow consultation exception [6]. Platforms operating legally in Washington will verify license status before scheduling a prescribing visit.

How to Get a Zetia Prescription Through Telehealth in Washington

Washington's telehealth infrastructure is mature. The state's 2017 Telemedicine Collaborative Access Act (SB 5389) requires most commercial insurers to cover telehealth visits at payment parity with in-person visits [7]. That means a video visit with a cardiologist or primary care provider for lipid management is reimbursable by most Washington private plans at the same rate as an office visit.

The standard telehealth pathway for ezetimibe in Washington runs in four steps. First, a patient schedules a video or phone visit with a Washington-licensed provider on a platform of their choice. Second, the provider reviews the patient's current lipid panel (a fasting result drawn within the past 6-12 months is acceptable to most clinicians). Third, if ezetimibe is appropriate, the provider sends an e-prescription directly to the patient's preferred Washington pharmacy. Fourth, the patient picks up the medication or arranges mail-order delivery.

Most telehealth platforms can complete steps one through three in a single visit lasting 20-30 minutes. Patients should have their most recent lipid panel results, a current medication list, and any prior authorization documentation ready before the visit. Platforms that specialize in preventive cardiology or metabolic health often have dedicated staff to handle prior authorization submissions the same day.

The Washington State Health Care Authority's telehealth policy explicitly permits audio-only visits for established patients when video is not available [8]. A patient without reliable internet access can complete a lipid management visit by phone with a Washington-licensed provider.

Required Labs Before Starting Ezetimibe in Washington

A fasting lipid panel is the non-negotiable baseline. Providers need total cholesterol, LDL-C (calculated or direct), HDL-C, and triglycerides to establish the starting LDL-C, set a treatment target, and document medical necessity for prior authorization purposes. Fasting for 9-12 hours before the draw is standard, though non-fasting panels are acceptable for initial screening per the 2018 ACC/AHA Guideline on Blood Cholesterol [3].

Liver function tests (AST, ALT) are not required before starting ezetimibe in patients who are not on a concurrent statin, but most Washington providers order them anyway because ezetimibe is almost always prescribed alongside statin therapy, and statins do carry a hepatotoxicity signal that warrants baseline liver enzymes [9]. Creatine kinase is ordered at baseline only if the patient reports muscle symptoms.

A complete metabolic panel, TSH (to rule out hypothyroidism as a secondary cause of hyperlipidemia), and fasting glucose or HbA1c round out the typical workup at most Washington clinics. Quest Diagnostics and LabCorp both have extensive Washington draw-site networks; most results return within 24-48 hours. Many primary care clinics and telehealth platforms in Washington can order labs digitally ahead of the visit so the provider has results in hand during the appointment [10].

Follow-up lipid panels are typically ordered 6-8 weeks after starting ezetimibe to confirm the expected 18-20% LDL-C reduction. If LDL-C remains above target at that point, the provider may discuss adding a PCSK9 inhibitor (evolocumab or alirocumab) per ACC/AHA 2022 guidance [3].

Washington Pharmacy Access: Retail, Mail-Order, and 503A Compounding

Generic ezetimibe 10 mg tablets are stocked at virtually every retail pharmacy chain operating in Washington, including Walgreens, CVS, Rite Aid, Bartell Drugs (a regional Washington chain), Fred Meyer Pharmacy, and Costco Pharmacy. GoodRx pricing for a 30-day supply of generic ezetimibe 10 mg in Seattle, Spokane, and Tacoma hovers between $12 and $22 without insurance as of mid-2025.

Mail-order pharmacies licensed to ship to Washington include OptumRx, Express Scripts, Walgreens Mail, and CVS Caremark. A 90-day supply via mail-order typically costs less than three individual 30-day fills. Shipping to most Washington ZIP codes takes 3-5 business days from the date the prescription is processed.

Washington permits 503A compounding pharmacies to prepare ezetimibe preparations (such as oral suspensions for patients who cannot swallow tablets) when a licensed prescriber provides a valid patient-specific prescription. The Washington State Department of Health licenses 503A pharmacies and requires them to comply with USP Chapter 795 standards [11]. Compounded ezetimibe is not interchangeable with commercially manufactured Zetia or its generics, and compounding is appropriate only when a commercial product does not meet the patient's clinical needs.

Brand-name Zetia carries a substantially higher retail price (often $300+ per month without insurance), so most Washington prescribers default to generic ezetimibe at the time of prescribing. Patients on brand-name Zetia may qualify for Merck's patient assistance program if their household income falls below 400% of the federal poverty level.

Washington Medicaid and Insurance Coverage for Ezetimibe

Washington Apple Health (Medicaid) covers ezetimibe for hyperlipidemia with prior authorization. The prior authorization criteria, published by the Washington State Health Care Authority, require documentation of [12]:

1. A diagnosis of hyperlipidemia, mixed dyslipidemia, homozygous familial hypercholesterolemia, or established atherosclerotic cardiovascular disease (ASCVD).
2. A current fasting lipid panel showing LDL-C at or above the patient's risk-stratified target.
3. A trial of at least one formulary statin at a tolerated dose for a minimum of 90 days, or documented statin intolerance with a specific adverse effect noted in the medical record.
4. The prescriber's attestation that ezetimibe is being added to (or replacing) statin therapy per evidence-based guidelines.

Most Washington Medicaid prior authorizations for ezetimibe are approved within 72 hours of submission when documentation is complete [12]. Telehealth platforms with dedicated prior authorization teams often submit on the patient's behalf the same day the prescription is written.

Commercial insurers in Washington (Regence, Premera, Kaiser Permanente WA, Molina, Coordinated Care) typically cover generic ezetimibe on Tier 2 or Tier 3 of their formularies. Copays range from $10 to $50 per 30-day supply depending on the plan. A step-therapy requirement (requiring statin trial first) is common but can usually be bypassed with a physician's letter of medical necessity if the patient has documented statin intolerance.

Medicare Part D covers generic ezetimibe across most Washington plan formularies. The Phase 1 deductible (up to $590 in 2025) applies before cost-sharing kicks in, but low-income subsidy (LIS/Extra Help) beneficiaries pay a nominal copay from the first fill.

Transferring an Existing Zetia Prescription to Washington

Patients relocating to Washington or establishing care with a new Washington provider can transfer an existing ezetimibe prescription from an out-of-state pharmacy to any Washington retail pharmacy. Federal law permits a one-time transfer for non-controlled substances between pharmacies in different states [13]. The receiving Washington pharmacist contacts the out-of-state pharmacy directly; the patient does not need to obtain a new prescription solely for the transfer.

If there are no refills remaining on the out-of-state prescription, the patient needs a new prescription from a Washington-licensed provider. A telehealth visit is the fastest path. Most platforms can complete the visit and transmit the e-prescription the same day, allowing a same-day pharmacy pickup at a Washington location.

Patients who previously filled Zetia through a mail-order pharmacy associated with an out-of-state employer health plan should confirm that their mail-order pharmacy is licensed to ship to Washington addresses. All major national mail-order pharmacies (OptumRx, Express Scripts, CVS Caremark, Walgreens Mail) hold Washington pharmacy licenses and can continue shipping without interruption after a patient moves to Washington.

Monitoring Ezetimibe Therapy Over Time

Ezetimibe therapy requires less intensive monitoring than statin therapy. After confirming LDL-C response at 6-8 weeks, most Washington providers shift to annual lipid panels for stable patients who have reached their LDL-C target. A systematic review of 27 randomized trials (N=22,054) published in JAMA Internal Medicine found that ezetimibe added to statin therapy produced no statistically significant increase in hepatotoxicity, myopathy, or rhabdomyolysis compared to placebo [14]. That safety profile supports the streamlined monitoring schedule.

Patients on concurrent statin plus ezetimibe who develop new-onset muscle pain should have a creatine kinase level drawn promptly. If CK exceeds 10 times the upper limit of normal, the statin should be stopped; ezetimibe itself does not cause myopathy and can generally be continued while the statin is held or switched [9].

Blood pressure, weight, and cardiovascular risk factor reassessment should occur at least annually. Washington's state-based quality improvement program (WSHA Collaborative Quality Initiatives) tracks lipid management metrics for participating practices, giving Washington patients an additional layer of care coordination [15].

Drug interactions are limited. Cyclosporine increases ezetimibe plasma levels roughly 3.4-fold; co-administration requires dose monitoring [2]. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption by approximately 55% and should be taken at least 2 hours before or 4 hours after ezetimibe [2]. No dose adjustment is required for concurrent warfarin, statins, or fibrates.

Ezetimibe vs. PCSK9 Inhibitors in Washington: Choosing the Right Second Agent

When a statin-intolerant patient or a very-high-risk ASCVD patient needs significant LDL-C lowering beyond what ezetimibe can provide, PCSK9 inhibitors (evolocumab 140 mg subcutaneous every 2 weeks, alirocumab 75-150 mg subcutaneous every 2-4 weeks) are the next step per the ACC/AHA 2022 guideline [3]. PCSK9 inhibitors lower LDL-C by 50-60% compared to ezetimibe's 18-20%, but their annual cost (often $6,000-$14,000 without assistance) far exceeds ezetimibe's cost.

The ACC/AHA guideline explicitly recommends a trial of ezetimibe before a PCSK9 inhibitor in most patients because of the cost difference and the comparable cardiovascular benefit per unit of LDL-C lowering [3]. The FOURIER trial (N=27,564) showed evolocumab reduced major cardiovascular events by 15% over a median 2.2 years (P<0.001) [16], while IMPROVE-IT showed ezetimibe reduced events by 6.4% over 7 years [1]. The difference in absolute benefit reflects both the greater LDL-C reduction with PCSK9 inhibitors and the shorter trial duration in FOURIER.

For Washington patients on Apple Health (Medicaid), PCSK9 inhibitors require prior authorization with evidence that ezetimibe at maximum dose was tried and failed to achieve the LDL-C target [12]. That step makes ezetimibe an almost universal prerequisite before PCSK9 inhibitor approval in the Washington Medicaid system.

The CLEAR Outcomes trial (N=13,970) published in NEJM in 2023 showed bempedoic acid (Nexletol) reduced major adverse cardiovascular events by 13% in statin-intolerant patients vs. placebo (P<0.001) [17]. Some Washington providers now use bempedoic acid alongside ezetimibe (the fixed-dose combination Nexlizet) as an alternative to PCSK9 inhibitors in statin-intolerant high-risk patients. Washington Medicaid covers this combination with prior authorization under similar criteria as ezetimibe monotherapy [12].

Lifestyle Factors Washington Prescribers Assess Alongside Ezetimibe

No medication works well in isolation. Washington providers prescribing ezetimibe routinely assess dietary saturated fat intake, physical activity, body weight, smoking status, and alcohol consumption at the initiating visit, because each of these factors independently affects LDL-C and cardiovascular risk.

Dietary changes alone can reduce LDL-C by 10-20% in motivated patients. Replacing saturated fat with polyunsaturated fat, reducing dietary cholesterol, and adding soluble fiber (oats, barley, psyllium) are the three dietary modifications with the strongest LDL-lowering evidence per the American Heart Association's 2021 Dietary Guidance [18]. Washington-based patients working with a registered dietitian alongside their prescribing provider may achieve better lipid outcomes than with medication alone.

Exercise (150 minutes per week of moderate-intensity aerobic activity per CDC physical activity guidelines) raises HDL-C by 3-9% and has modest effects on LDL-C [19]. Weight loss of 10 pounds lowers LDL-C by approximately 8 mg/dL on average [18]. These lifestyle numbers matter because they determine how much pharmacological work ezetimibe has to do.

Washington providers documenting lifestyle counseling also satisfy the ACC/AHA guideline's requirement that statin and non-statin therapy be initiated alongside "lifestyle modification as the cornerstone of ASCVD risk reduction" [3]. That documentation supports prior authorization approvals for both ezetimibe and downstream PCSK9 inhibitor therapy if needed.